The Votes Are In ! ASH Announces Executive Committee Election Results
Robert Brodsky , MD Cynthia Dunbar , MD Jamile Shammo , MD
The American Society of Hematology ( ASH ) has announced the election of four new members to its Executive Committee for terms beginning after the 2020 ASH Annual Meeting in December .
• Robert Brodsky , MD , will serve a 1-year term as vice president , followed by successive terms as president-elect and president .
• Cynthia Dunbar , MD , will serve a 4-year term as secretary .
• Jamile Shammo , MD , and Betty Pace , MD , will each serve 4-year terms as councillors .
Dr . Brodsky is a professor of medicine and oncology and the director of the Division of Hematology at Johns Hopkins School of Medicine in Baltimore , where he is also the director of the Physician- Scientist Pathway for the Osler Medical
Betty Pace , MD
Training Program . His research interests include bone marrow failure states , bone marrow transplantation for nonmalignant diseases , complement and complement-related disorders , paroxysmal nocturnal hemoglobinuria , atypical hemolytic uremic syndrome , and antiphospholipid antibody syndrome .
Dr . Brodsky has been a dedicated ASH volunteer , currently completing his term as the Society ’ s secretary . An ASH member since 1992 , Dr . Brodsky has chaired the ASH Scientific Committee on Bone Marrow Failure and has served on the Program Committee since 2014 , including cochairing the 2016 Scientific Program . Dr . Brodsky currently serves on the Task Force on Immunotherapies and also served on the editorial board of ASH ’ s journal Blood .
“ My experiences working on various ASH programs have provided me with a deep appreciation and understanding of the Society ’ s mission to promote research , clinical care , training , and advocacy in hematology ,” Dr . Brodsky said . “ As I look toward the next few years , recruiting , inspiring , training ,
and mentoring the next generation of hematologists is of clear importance . We need to recruit a diverse , inclusive workforce to treat hematology patients and ensure that early-career investigators can access research funding that allows them to pursue clinical and laboratory-based research .”
Dr . Dunbar , secretary-elect , is the branch chief of the Division of Intramural Research at the National Institutes of Health ’ s National Heart , Lung , and Blood Institute and former editor-in-chief of Blood . Her research interests include laboratory research on hematopoiesis , natural killer cell biology , CAR T cells , hematopoietic stem cell gene therapy , bone marrow failure syndromes , stem cell mobilization and engraftment , and stem cell transplantation .
Dr . Shammo , councillor-elect , is a professor of medicine and pathology of the section of Hematology and Stem Cell Transplantation , Division of Hematology / Oncology at Rush University Medical Center in Chicago . Her research interests include myelodysplastic syndromes , myeloproliferative neoplasms ( MPN ), and bone marrow failure .
Dr . Pace , councillor-elect , is a professor of pediatrics and Francis J . Tedesco Distinguished Chair of Pediatric Hematology / Oncology , Department of Pediatrics ; a professor of biochemistry and molecular biology ; and a professor of graduate studies at the Medical College of Georgia , Augusta University . Her research interests include drug discovery to treat sickle cell disease , mechanisms of globin gene regulation , and training junior investigators and increasing diversity in the hematology workforce .
Congratulations to the newest members of the ASH Executive Committee !
Now Published : ASH Clinical Practice Guidelines on the Treatment of DVT and PE
ASH ’ s new clinical practice guidelines on the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ) in patients without cancer are now published in Blood Advances .
These are part of a series of 11 guidelines ASH is developing on venous thromboembolism ( VTE ) with support from the McMaster University GRADE Centre in Canada .
Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise , use of an international normalized ratio ( INR ) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist ( VKA ) for secondary prevention , and use of indefinite anticoagulation for patients with recurrent unprovoked VTE . Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE .
According to guideline Treatment Panel Chair Thomas Ortel , MD , PhD , of Duke University in Durham , North Carolina , these guidelines allow “ a practicing physician anywhere in the United States [ to ] put together a recommendation for a patient and know that it ’ s based on the best available data and the best synthesis of [ those ] data .”
Find the guidelines and learn more at hematology . org / VTEguidelines .
62 ASH Clinical News November 2020